Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 24;74(1):133–147. doi: 10.1002/hep.31750

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 PathAI. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

FIG. 3 — Application of ML features for assessing prognosis and monitoring responses to treatment and disease progression. Kaplan‐Meier curves showing proportions of patients with bridging fibrosis (F3) without progression to cirrhosis (left panel, STELLAR‐3) or patients with cirrhosis (F4) without liver‐related clinical events (right panel, STELLAR‐4) over time. Patients are categorized into subgroups by tertile of (A) percentage of area predicted to be NASH CRN stage 4, (B) ratio of steatosis to HB, and (C) percent area of portal inflammation based on ML predictions. Tertiles are shown by shades of green (STELLAR‐3) and blue (STELLAR‐4), with the lightest shades indicating the bottom tertile and darkest shades the top tertile. P values were computed using the log‐rank test.